Ernexa Therapeutics (ERNA) EBITDA Margin (2016 - 2024)
Historic EBITDA Margin for Ernexa Therapeutics (ERNA) over the last 14 years, with Q4 2024 value amounting to 14194.74%.
- Ernexa Therapeutics' EBITDA Margin fell 24294300.0% to 14194.74% in Q4 2024 from the same period last year, while for Sep 2025 it was 52215.79%, marking a year-over-year decrease of 492408700.0%. This contributed to the annual value of 2612.33% for FY2024, which is 185226700.0% up from last year.
- Latest data reveals that Ernexa Therapeutics reported EBITDA Margin of 14194.74% as of Q4 2024, which was down 24294300.0% from 463.86% recorded in Q3 2024.
- In the past 5 years, Ernexa Therapeutics' EBITDA Margin ranged from a high of 99142.86% in Q2 2022 and a low of 14194.74% during Q4 2024
- Its 4-year average for EBITDA Margin is 3706.23%, with a median of 463.86% in 2024.
- As far as peak fluctuations go, Ernexa Therapeutics' EBITDA Margin tumbled by -973659000bps in 2023, and later soared by 103302600bps in 2024.
- Ernexa Therapeutics' EBITDA Margin (Quarter) stood at 26.47% in 2020, then soared by 374475bps to 99142.86% in 2022, then plummeted by -112bps to 11765.31% in 2023, then dropped by -21bps to 14194.74% in 2024.
- Its EBITDA Margin stands at 14194.74% for Q4 2024, versus 463.86% for Q3 2024 and 10491.49% for Q2 2024.